BioMarin Pharmaceuticals
June 24, 2026
Theater 4
Type: Company Presentation
Focus Area:
Orphan and Rare Disease
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.
Company HQ City:
San Rafael
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
1997
Lead Product in Development:
VOXZOGO; multiple investigational products in development
CEO
Alexander Hardy
Development Phase of Lead Product
Multiple Products in Market
Exchange
Nasdaq
Ticker
BMRN
When you expect your next catalyst update?
Q2 2026
What is your next catalyst (value inflection) update?
The expected closing of BioMarin’s acquisition of Amicus Therapeutics in the second quarter represents a significant upcoming milestone. The transaction is anticipated to expand BioMarin’s portfolio of therapies for rare genetic diseases and strengthen the company’s commercial and development capabilities in the rare disease space. Completion of the acquisition is expected to enhance BioMarin’s long-term growth profile and create new opportunities to advance innovative treatments for patients with high unmet medical needs.
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}